In a significant overseas acquisition, Sun Pharmaceutical Industries, India’s largest pharmaceutical company, and US-based Organon & Co have announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion (around Rs 1.10 lakh crore).

Organon, based in New Jersey and listed on the New York Stock Exchange, is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the US and Canada, in 2021.…